Literature DB >> 28461525

International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting.

Laura C Coates1,2, Vinod Chandran3,4, Alexis Ogdie3,4, Denis O'Sullivan3,4, Mel Brooke3,4, Ingrid Steinkoenig3,4, Philip J Mease3,4, Christopher T Ritchlin3,4, Arthur Kavanaugh3,4.   

Abstract

At the 2016 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the treatment recommendations committee summarized its work and presented its plans for future updates. The committee announced a partnership between GRAPPA and Guideline Central to develop a pocket reference guide to the treatment recommendations. Because key new data appear regularly, the group discussed publishing periodic updates of the recommendations online through the GRAPPA Website as well as a goal of publishing another major update of the recommendations in 2020. The committee also announced that 2 GRAPPA members were awarded a grant from the International League of Associations for Rheumatology to look at potential adaptations of international treatment recommendations for resource-poor settings, particularly in South America and Africa.

Entities:  

Keywords:  COMORBIDITIES; DACTYLITIS; ENTHESITIS; NAIL DISEASE; PSORIASIS; PSORIATIC ARTHRITIS

Mesh:

Year:  2017        PMID: 28461525     DOI: 10.3899/jrheum.170144

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

Review 1.  The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis.

Authors:  Leticia Garcia-Montoya; Helena Marzo-Ortega
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-09-06       Impact factor: 5.346

Review 2.  The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis.

Authors:  Matteo Vecellio; Vivien Xanath Hake; Connor Davidson; Maria Cristina Carena; B Paul Wordsworth; Carlo Selmi
Journal:  Front Immunol       Date:  2021-01-07       Impact factor: 7.561

3.  Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).

Authors:  Michelle L M Mulder; Johanna E Vriezekolk; Nathan den Broeder; Elien A M Mahler; Philip S Helliwell; Frank H J van den Hoogen; Alfons A den Broeder; Mark H Wenink
Journal:  Trials       Date:  2020-02-10       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.